Regeneron Pharmaceuticals
(REGN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,506,400 | 1,995,800 | 3,090,200 | 2,488,200 | 2,011,800 |
| Marketable Securities | 5,937,200 | 5,473,800 | 5,259,200 | 6,524,300 | 7,784,700 |
| Receivables | 5,687,100 | 5,610,000 | 5,561,000 | 6,211,900 | 6,107,100 |
| Inventories | 3,254,400 | 3,205,600 | 3,192,400 | 3,087,300 | 3,018,000 |
| TOTAL | $17,980,700 | $16,859,500 | $17,571,700 | $18,660,900 | $19,333,600 |
| Non-Current Assets | |||||
| PPE Net | 5,002,300 | 4,840,700 | 4,694,200 | 4,599,700 | 4,439,200 |
| Investments And Advances | 10,285,700 | 10,058,200 | 9,276,300 | 8,900,100 | 8,490,900 |
| Intangibles | 1,380,900 | 1,351,700 | 1,167,000 | 1,148,600 | 1,120,100 |
| Other Non-Current Assets | 5,519,800 | 5,109,100 | 4,836,000 | 4,450,100 | 4,058,100 |
| TOTAL | $22,188,700 | $21,359,700 | $19,973,500 | $19,098,500 | $18,108,300 |
| Total Assets | $40,169,400 | $38,219,200 | $37,545,200 | $37,759,400 | $37,441,900 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 903,800 | 723,900 | 705,500 | 789,500 | 497,300 |
| Other current liabilities | 2,975,700 | 2,461,200 | 2,241,800 | 2,527,100 | 2,536,500 |
| TOTAL | $4,425,100 | $3,667,000 | $3,566,600 | $3,944,300 | $3,661,000 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,985,500 | 1,985,100 | 1,984,800 | 1,984,400 | 1,984,000 |
| Deferred Revenues | 545,600 | 481,900 | 619,300 | 627,700 | 627,200 |
| Other Non-Current Liabilities | 1,861,800 | 1,701,900 | 1,674,400 | 1,571,400 | 1,543,600 |
| TOTAL | $4,786,500 | $4,613,300 | $4,591,000 | $4,461,500 | $4,455,000 |
| Total Liabilities | $9,211,600 | $8,280,300 | $8,157,600 | $8,405,800 | $8,116,000 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 105,100 | 105,987 | 107,966 | 109,325 | 109,890 |
| Common Shares | 100 | 100 | 100 | 100 | 100 |
| Retained earnings | 35,045,800 | 33,680,200 | 32,384,400 | 31,672,900 | 30,755,200 |
| Other shareholders' equity | 68,600 | 52,800 | 29,000 | -8,300 | 59,800 |
| TOTAL | $30,957,800 | $29,938,900 | $29,387,600 | $29,353,600 | $29,325,900 |
| Total Liabilities And Equity | $40,169,400 | $38,219,200 | $37,545,200 | $37,759,400 | $37,441,900 |